Cooperative Agreement U01CA290442
Award Date
9/20/24
Completion Date
8/31/29
Dollars Obligated
$558K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Cooperative Agreement
Place of Performance
Clemson, SC 29634, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
This federal Cooperative Agreement award for $811,500.00 from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research to bridge the gap between bioinformatics and mathematical modeling for patient-specific tumor modeling. The project aims to merge bioinformatics software for analyzing single-cell and spatial multi-omics data with an agent-based modeling framework to simulate cell interactions in virtual tumor environments. Key objectives include refining a cell...
The National Cancer Institute (NCI) awarded a $954,000 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Pittsburgh to investigate how aging promotes the growth of glioblastoma, one of the most lethal forms of cancer. The research aims to leverage insights from the biology of neural stem cells and the molecular circuitry of cancer stem cells to understand how aging creates a tumor microenvironment that supports the survival and proliferation of glioblastoma. The...
The National Cancer Institute (NCI) awarded a $877,856 Cooperative Agreement under the Cancer Biology Research (CFDA 93.396) program to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to develop the Galaxy for Cancer (Galaxy-C) computational workbench. The goal is to create a platform that enables cancer researchers, especially those with limited computational skills, to more easily access, analyze, and extract insights from diverse cancer datasets and analysis tools....
The National Cancer Institute (NCI) awarded a $552,968 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Pittsburgh to conduct research on the role of tRNA modifications in glioblastoma stem cell maintenance and translational reprogramming. The project aims to use mass spectrometry and ribosome profiling to investigate how altered tRNA modifications influence the translational landscape and drive oncogenic processes in glioblastoma, a highly lethal...
The National Cancer Institute (NCI) awarded a $585,931 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Pittsburgh. The grant, effective February 3, 2025 through January 31, 2030, will support a research project titled "Single-Cell Congruence Evaluation and Selection of Cancer Models Towards Precision Medicine." The project aims to: 1) Identify and clinically annotate prevalent subclones and tumor microenvironment cell types in breast cancer,...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) will provide $136,412 to the Regents of the University of Michigan to conduct research on defining and interrupting metabolic crosstalk in the glioblastoma (GBM) microenvironment. The primary goals are to: 1) determine mechanistically how metabolite exchange between normal brain cells and GBM cancer cells promotes tumor growth and therapy resistance; 2) investigate the impact of disrupting...
The National Cancer Institute (NCI) awarded a $831,565 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of Massachusetts Medical School (UMass Medical) to develop an Integrative Analysis and Visualization Platform for Cancer Regulatory Genomics. The project aims to create a Regulatory-Element-Target-Gene Atlas that will enable researchers to explore connections between regulatory elements and genes associated with cancer. It will also perform...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas M.D. Anderson Cancer Center provides $432,134.00 in funding to establish a radiotheranostic approach for treating glioblastoma (GBM), a highly aggressive brain cancer, by targeting the IL13RA2 protein expressed on cancer cells. The research aims to develop human monoclonal antibodies that bind to IL13RA2 with high affinity and specificity, and evaluate the...